C. Dominguez

L. Mrzljak, C. Dominguez, S. Stroobants, 2019, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem

L. Mrzljak, C. Dominguez, S. Stroobants, 2022, The Journal of Nuclear Medicine.

The de novo design and synthesis of cyclic urea inhibitors of factor Xa: optimization of the S4 ligand.

C. Dominguez, T. Maduskuie, R. Knabb, 2000, Bioorganic & medicinal chemistry letters.

Biaryl substituted alkylboronate esters as thrombin inhibitors

J. Wityak, P. Weber, C. Dominguez, 1997 .

A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasma.

C. Dominguez, Laura Orsatti, F. Bonelli, 2015, Journal of pharmaceutical and biomedical analysis.

Modelling the Human Blood–Brain Barrier in Huntington Disease

S. Fortuni, C. Dominguez, Giulio Auciello, 2022, International journal of molecular sciences.

Azole-based inhibitors of AKT/PKB for the treatment of cancer.

Daniel J. Freeman, Q. Zeng, Guomin Yao, 2010, Bioorganic & medicinal chemistry letters.

Effect of microwave heating on Ullmann-type heterocycle-aryl ether synthesis using chloro-heterocycles

C. Dominguez, R. Hungate, Tae-Seong Kim, 2006 .

Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).

S. Harper, C. Dominguez, L. Tomei, 2017, Archives of biochemistry and biophysics.

A soluble base for the copper-catalyzed imidazole N-arylations with aryl halides.

C. Dominguez, R. Hungate, Longbin Liu, 2005, The Journal of organic chemistry.

N-Aryl-γ-lactams as integrin αvβ3 antagonists

Jiandong Zhang, A. Tasker, C. Dominguez, 2004 .

Validation, kinetic modeling, and test-retest reproducibility of [18F]SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2A in mice

C. Dominguez, S. Stroobants, Yuchuan Wang, 2022, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins.

J. Wityak, C. Halldin, K. Varnäs, 2021, Journal of medicinal chemistry.

Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.

R. Bürli, M. Lamers, G. Mcallister, 2016, ACS medicinal chemistry letters.

Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's Disease.

S. Steinbacher, R. Cachope, J. Tierney, 2022, Journal of medicinal chemistry.

Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.

J. Treanor, C. Dominguez, J. Katon, 2007, Journal of medicinal chemistry.

Synthesis of isothiocyanato-1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidines, potential irreversible ligands at the dopamine re-uptake site

C. George, C. Dominguez, B. Costa, 1992 .

Synaptic vesicle glycoprotein 2A is affected in the CNS of Huntington's Disease mice and post-mortem human HD brain.

L. Mrzljak, C. Dominguez, S. Stroobants, 2021, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington’s Disease Pathology

T. Vogt, G. Mcallister, C. Dominguez, 2022, Journal of medicinal chemistry.

Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin

G. Bormans, C. Dominguez, W. Vandenberghe, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.

R. Bürli, M. Lamers, C. Dominguez, 2019, Bioorganic & medicinal chemistry letters.

Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.

T. Harvey, R. Syed, C. Dominguez, 2005, Bioorganic & medicinal chemistry letters.

A Label-Free LC/MS/MS-Based Enzymatic Activity Assay for the Detection of Genuine Caspase Inhibitors and SAR Development

C. Dominguez, D. Winkler, F. Krieger, 2013, Journal of biomolecular screening.

Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin

G. Bormans, C. Dominguez, W. Vandenberghe, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial SAR studies.

C. Dominguez, T. Maduskuie, R. Knabb, 1998, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.

R. Bürli, M. Lamers, G. Mcallister, 2013, Journal of medicinal chemistry.

A novel synthesis of 3,4-disubstituted cinnolines from o-trifluorophenyl hydrazones

C. Dominguez, A. Kiselyov, 1999 .

Synthesis and evaluation of conformationally restricted N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamines at sigma receptors. 2. Piperazines, bicyclic amines, bridged bicyclic amines, and miscellaneous compounds.

W. Bowen, J. Linders, C. Dominguez, 1993, Journal of medicinal chemistry.

A Novel Synthesis of 3,4-Disubstituted Cinnolines from o-Trifluorophenyl Hydrazones.

C. Dominguez, A. Kiselyov, 1999 .

Synthesis and biological evaluation of conformationally restricted 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylenediam ines as sigma receptor ligands. 1. Pyrrolidine, piperidine, homopiperidine, and tetrahydroisoquinoline classes.

W. Bowen, C. Dominguez, L. Radesca, 1992, Journal of medicinal chemistry.

Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives.

K. Rex, Matthew R. Lee, C. Dominguez, 2012, Journal of medicinal chemistry.

Design, synthesis, and biological evaluation of potent c-Met inhibitors.

Yuan Cheng, K. Rex, A. Coxon, 2008, Journal of medicinal chemistry.

Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepine receptors.

P. Skolnick, C. Dominguez, K. Rice, 1993, Journal of medicinal chemistry.

Assessment of chloroquine treatment for modulating autophagy flux in brain of WT and HD mice.

D. Marchionini, C. Dominguez, H. Birch, 2014, Journal of Huntington's disease.

Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.

C. Dominguez, F. Eustache, F. Krieger, 2011, Bioorganic & medicinal chemistry.

An efficient one-pot construction of substituted pyrimidinones

C. Dominguez, M. Bartberger, P. Ibrahim, 2006 .

Establishment of an in Vitro Human Blood-Brain Barrier Model Derived from Induced Pluripotent Stem Cells and Comparison to a Porcine Cell-Based System

C. Dominguez, Giulio Auciello, A. Di Marco, 2020, Cells.

4-Alkyl- and 4-cinnamylglutamic acid analogues are potent GluR5 kainate receptor agonists.

B. Ballyk, C. Dominguez, D. Bleakman, 2000, Journal of medicinal chemistry.

MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein.

Matthew R. Lee, C. Dominguez, Matthew R Lee, 2005, Current medicinal chemistry.

A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease

S. Dowler, J. Wityak, G. Mcallister, 2014, PloS one.

Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr.

A. Coxon, T. Harvey, R. Syed, 2007, Bioorganic & medicinal chemistry letters.

A new apo-caspase-6 crystal form reveals the active conformation of the apoenzyme.

M. Lamers, C. Dominguez, A. Kiselyov, 2011, Journal of molecular biology.

Foundation-directed therapeutic development in Huntington's disease.

C. Dominguez, I. Muñoz-Sanjuán, 2014, Journal of medicinal chemistry.

High-Content Screening Analysis of the p38 Pathway: Profiling of Structurally Related p38α Kinase Inhibitors Using Cell-Based Assays

C. Dominguez, D. Powers, S. Ross, 2006 .

Structure of human caspase-6 in complex with Z-VAD-FMK: New peptide binding mode observed for the non-canonical caspase conformation.

M. Lamers, C. Dominguez, A. Kiselyov, 2011, Bioorganic & medicinal chemistry letters.

Pharmacokinetics of memantine in rats and mice

C. Dominguez, D. Howland, M. Beconi, 2011, PLoS currents.

Elevated Type 1 Metabotropic Glutamate Receptor Availability in a Mouse Model of Huntington’s Disease: a Longitudinal PET Study

L. Mrzljak, C. Dominguez, S. Stroobants, 2020, Molecular Neurobiology.

p38 Inhibitors: beyond pyridinylimidazoles

C. Dominguez, Dawei Zhang, N. Tamayo, 2005 .

IKBKB reduces huntingtin aggregation by phosphorylating serine 13 via a non-canonical IKK pathway

A. Caricasole, C. Dominguez, Ramee Lee, 2022, Life Science Alliance.

Ultrasensitive quantitative measurement of huntingtin phosphorylation at residue S13.

D. Lavery, A. Caricasole, H. Lashuel, 2020, Biochemical and biophysical research communications.

Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates

J. Wityak, H. Lashuel, C. Scheich, 2021, Scientific Reports.

Development of a ligand for in vivo imaging of mutant huntingtin in Huntington’s disease

D. Marchionini, A. Van der Linden, L. Mrzljak, 2022, Science Translational Medicine.

A novel imaging ligand as a biomarker for mutant huntingtin-lowering in Huntington’s disease

D. Marchionini, A. Van der Linden, L. Mrzljak, 2021, bioRxiv.

Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.

G. Mcallister, C. Dominguez, V. Beaumont, 2021, ACS medicinal chemistry letters.

A Profiling Platform for the Characterization of Transglutaminase 2 (TG2) Inhibitors

J. Wityak, C. Dominguez, R. Pacifici, 2010, Journal of biomolecular screening.

Synthesis of Mono-Fluoromethyl 6,5-Heteroaromatic Bicycles Using 1,3-Difluoroacetone as a Cyclising Reagent

C. Dominguez, Longbin Liu, Karine Malagu, 2022, Social Science Research Network.

Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.

David D. Manning, J. Wityak, D. Kitchen, 2015, Journal of medicinal chemistry.

Kinetic Modelling and Test–Retest Reproducibility for the Dopamine D1R Radioligand [11C]SCH23390 in Healthy and Diseased Mice

C. Dominguez, S. Stroobants, S. Staelens, 2020, Molecular Imaging and Biology.

The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease

L. Mrzljak, C. Dominguez, D. Winkler, 2016, Experimental Neurology.

Efficacy of Selective PDE4D Negative Allosteric Modulators in the Object Retrieval Task in Female Cynomolgus Monkeys (Macaca fascicularis)

C. Dominguez, V. Beaumont, M. Beconi, 2014, PloS one.

Conformational dynamics and DNA recognition by human MutSβ

S. Steinbacher, T. Vogt, C. Dominguez, 2023, bioRxiv.

Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington’s disease

L. Mrzljak, C. Dominguez, S. Stroobants, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Longitudinal Characterization of mGluR5 Using 11C-ABP688 PET Imaging in the Q175 Mouse Model of Huntington Disease

J. Wityak, L. Mrzljak, C. Dominguez, 2018, The Journal of Nuclear Medicine.

MR-based spatial normalization improves [18F]MNI-659 PET regional quantification and detectability of disease effect in the Q175 mouse model of Huntington’s disease

A. Van der Linden, J. Wityak, L. Mrzljak, 2018, PloS one.

Noninvasive Relative Quantification of [11C]ABP688 PET Imaging in Mice Versus an Input Function Measured Over an Arteriovenous Shunt

M. Verhoye, A. Van der Linden, J. Wityak, 2018, Front. Neurol..

Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.

Andreas Ebneth, Sabine Schaertl, Andreas Scheel, 2012, Journal of medicinal chemistry.

The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington’s Disease

G. Bates, C. Dominguez, S. Ramboz, 2014, PLoS currents.

4-Alkylidenyl glutamic acids, potent and selective GluR5 agonists.

B. Ballyk, C. Dominguez, D. Bleakman, 2000, Bioorganic & medicinal chemistry letters.

Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo

R. Bürli, G. Bates, G. Mcallister, 2012, PloS one.

Validation of LC-MS/MS methods for quantitative analysis of kynurenine pathway metabolites in human plasma and cerebrospinal fluid.

C. Dominguez, V. Khetarpal, Bryan D. Marks, 2023, Bioanalysis.

SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease.

J. Wityak, C. Dominguez, M. Beconi, 2012, ACS medicinal chemistry letters.

Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.

J. Wityak, C. Dominguez, O. Ichihara, 2012, ACS medicinal chemistry letters.

Metabolism and Pharmacokinetics of JM6 in Mice: JM6 Is Not a Prodrug for Ro-61-8048

C. Dominguez, D. Winkler, M. Beconi, 2012, Drug Metabolism and Disposition.

Imaging Mutant Huntingtin Aggregates: Development of a Potential PET ligand.

J. Wityak, C. Halldin, L. Mrzljak, 2020, Journal of medicinal chemistry.

Evaluation of 5 ‑ (Tri ﬂ uoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington ’ s Disease

G. Mcallister, C. Dominguez, V. Beaumont, 2021 .

Novel and Highly Efficient Synthesis of Substituted Dibenz[b,g]1,5-oxazocines. A Direct Comparison of the Solution versus Solid-Phase Approach

C. Dominguez, Zhidong Chen, A. Kiselyov, 2000 .

Prodrug for Ro-61-8048

C. Dominguez, D. Winkler, M. Beconi, 2012 .

Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction.

S. Steinbacher, M. Augustin, S. Harper, 2020, ACS medicinal chemistry letters.

Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor

R. Bürli, M. Lamers, C. Dominguez, 2018 .

Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction.

S. Steinbacher, M. Augustin, C. Dominguez, 2020, Bioorganic & medicinal chemistry.

Development of LC/MS/MS, High-Throughput Enzymatic and Cellular Assays for the Characterization of Compounds That Inhibit Kynurenine Monooxygenase (KMO)

C. Dominguez, D. Winkler, M. Beconi, 2013, Journal of biomolecular screening.

Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex

J. Wityak, C. Halldin, K. Varnäs, 2017, The Journal of Nuclear Medicine.

Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's Disease.

C. Dominguez, T. Heikkinen, T. Bolkvadze, 2023, Journal of medicinal chemistry.

Metabolism and Pharmacokinetics of JM6 in Mice: JM6 Is Not a Prodrug for Ro-61-8048

C. Dominguez, D. Winkler, M. Beconi, 2012, Drug Metabolism and Disposition.

Selective β-Hydroxyethylation at the N-1 Position of a Pyrazolone: Synthesis of Benzyl 1-(β-Hydroxyethyl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylate

R. Bürli, C. Dominguez, Longbin Liu, 2008 .

Design and Evaluation of [18F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin Aggregates.

C. Halldin, C. Dominguez, Laura Orsatti, 2022, Journal of medicinal chemistry.

Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.

M. Lamers, R. Cachope, G. Mcallister, 2021, Journal of medicinal chemistry.

A new approach to the design of sigma-2-selective ligands: synthesis and evaluation of N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1- pyrrolidinyl)ethylamine-related polyamines at sigma-1 and sigma-2 receptor subtypes.

W. Bowen, C. Dominguez, B. de Costa, 1994, Journal of medicinal chemistry.